Live Breaking News & Updates on Stefano colloca

Stay informed with the latest breaking news from Stefano colloca on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Stefano colloca and stay connected to the pulse of your community

Viral-Vector Vaccine Manufacturing - BioProcess International

Viral vector vaccines receive far less attention, but they merit serious consideration because they hold much promise for mitigating infectious diseases.

New-york , United-states , India , Chad , Rome , Lazio , Italy , Netherlands , Sudan , Semliki , Bundibugyo , Uganda

ReiThera receives AIFA approval to open new production facility in Italy

AIFA has granted operational authorisation to ReiThera to open its new production area at its pharmaceutical facility at the Castel Romano Technopole.

Stefano-colloca , Respiratory-syncytial-virus ,

ReiThera expands large-scale viral vector production capabilities with opening of new manufacturing facility

/PRNewswire/ -- ReiThera, a biotech company dedicated to the development of new technologies, GMP production and the clinical translation of genetic vaccines...

Italy , Rome , Lazio , Italian , Prnewswire-reithera , Stefano-colloca , George-underwood , Castel-romano-technopole , Shaad-cajee , Sylvie-berrebi , Reithera-srl , Contract-development

ReiThera Srl: ReiThera expands large-scale viral vector production capabilities with opening of new manufacturing facility

- New 1,500 sq.m. facility granted operational authorisation from AIFA, the Italian Medicines Agency, to enable production scales of up to 3,000 liters; - New facility will allow ReiThera

Italy , Rome , Lazio , Italian , Reithera-castel-romano-technopole , Prnewswire-reithera , George-underwood , Shaad-cajee , Sylvie-berrebi , Kostenloser-wertpapierhandel , Stefano-colloca , Castel-romano-technopole

ReiThera and Exothera Collaborate to Develop Large-scale, Low Cost per Dose Manufacturing Process to Deliver Novel Vaccines to Low- and Middle-Income Countries

/PRNewswire/ -- ReiThera Srl, a biotech company dedicated to the technology development, GMP manufacturing and clinical translation of genetic vaccines and...

Italy , Rome , Lazio , Univercells-technologie-nevoline , Stefano-colloca , Reithera-srl , Linkedin , Melinda-gates-foundation , Chief-technology-officer , Thera-srl , Respiratory-syncytial-virus , Exothera

ReiThera: Bill Gates funds Made in Italy covid vaccine

The Bill and Melinda Gates Foundation has awarded a grant of $1.4 million to Italian biotech firm ReiThera for the development of covid-19 and HIV vaccines.

Italy , Rome , Lazio , Castel-romano , Molise , Italian , Stefano-colloca , Melinda-gates-foundation , Italy-news-in-english , Ovid-19 , Eithera-vaccine , Ome

ReiThera Awarded Grant to Develop Next Generation Vaccines

/PRNewswire/ -- ReiThera Srl, a biotech company dedicated to the technology development, GMP manufacturing and clinical translation of genetic vaccines and...

Italy , Rome , Lazio , Italian , Stefano-colloca , George-underwood , Giorgia-bazurli , Antonella-folgori , Prnewswire-reithera-srl , Sylvie-berrebi , Reithera-srl , Melinda-gates-foundation

ReiThera Srl: ReiThera Awarded Grant to Develop Next Generation Vaccines

Program funded by the Bill & Melinda Gates Foundation will use ReiThera's GRAd platform technology to develop next generation vaccines against SARS-CoV-2 emerging variants and HIV ROME

Italy , Rome , Lazio , Italian , George-underwood , Giorgia-bazurli , Antonella-folgori , Sylvie-berrebi , Stefano-colloca , Kostenloser-wertpapierhandel , Reithera-srl , Prnewswire-reithera-srl

The Fiji Times » Global quest underway to speed COVID-19 vaccine trials

Reuters Reuters
21 July, 2021, 2:10 pm
Vials labelled "Moderna, Johnson & Johnson, Pfizer-BioNTech coronavirus disease (COVID-19) vaccine" are seen in this illustration picture taken May 2, 2021. REUTERS/Dado Ruvic
CHICAGO, July 20 (Reuters) – Scientists are working on a benchmark for COVID-19 vaccine efficacy that would allow drugmakers to conduct smaller, speedier human trials to get them to market and address a huge global vaccine shortage.
Researchers are trying to determine just what level of COVID-19 antibodies a vaccine must produce to provide protection against the illness. Regulators already use such benchmarks – known as correlates of protection – to evaluate flu vaccines without requiring large, lengthy clinical trials.

New-york , United-states , Australia , Taiwan , United-kingdom , Italy , France , Jordan , Chicago , Illinois , French , British

Global quest underway to speed up COVID-19 vaccine trials

Jul 21, 2021
CHICAGO – Scientists are working on a benchmark for COVID-19 vaccine efficacy that would allow drugmakers to conduct smaller, speedier human trials to get them to market and address a huge global vaccine shortage.
Researchers are trying to determine just what level of COVID-19 antibodies a vaccine must produce to provide protection against the illness. Regulators already use such benchmarks — known as correlates of protection — to evaluate flu vaccines without requiring large, lengthy clinical trials.
“You could use it to predict efficacy from a vaccine, which will be more important as we are less able to conduct placebo-controlled trials,” said Stanley Plotkin, inventor of the Rubella vaccine and an expert on correlates of protection.

New-york , United-states , Australia , Taiwan , United-kingdom , Italy , France , Jordan , Chicago , Illinois , Britain , French